HealthyNCT07657221
Impact of Risk Feedback on Behavioral Trajectories
A study testing PHEN feedback and PHEN+GENE Feedback in people with Healthy and Alcohol Consumption, run by University of Southern California at 1 site in United States.
Trial summary
The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. Read more about this study
- Who is it for?
- Ages 17 to 25 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy, Alcohol Consumption
- What is being tested?
- PHEN feedback and PHEN+GENE Feedback
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 450 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Aug 2026to 31 Aug 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 25 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- USC student of Chinese, Japanese, Korean, or Vietnamese heritage
Who cannot join
- not a USC student, not 17-25 years old, not of Chinese, Japanese, Korean, or Vietnamese heritage
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Southern California
Los Angeles, California, 90089
Susan Luczak, PhD, 2137402203, luczak@usc.edu
About this study
Official title: Alcohol Metabolism and Disease Risk in Asians: Examining the Impact of Personalized Phenotypic/Genotypic Feedback on Early Drinking Trajectories
The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. The main research question is: can we affect young adult behaviors through communication about these health-related risks? Participants will be asked to complete an in-person baseline session where they provide a DNA sample, complete online surveys, and do a brief interview. They will then receive one of several brief online information sessions and be followed in online surveys approximately every 3 months over the next 2 years.
- Conditions
- Healthy, Alcohol Consumption
- Being tested
- PHEN feedback, PHEN+GENE Feedback, Control
- Medical subject headings
- Alcohol Drinking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PHEN feedbackBehavioural
Feedback on alcohol response (phenotype)
PHEN+GENE FeedbackGenetic
Feedback on both phenotype and genotype (PHEN+GENE)
ControlOther
Feedback that serves as control
| Study group | Role | What they receive |
|---|---|---|
| PHEN | Experimental | provided phenotypic feedback Receives: Behavioral: PHEN feedback |
| GENE | Experimental | provides genotypic feedback Receives: Behavioral: PHEN feedback; Genetic: PHEN+GENE Feedback |
| CONTROL | Placebo comparator | provided a control feedback Receives: Other: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Drinking frequency
Number of days consumed alcohol
Measured: up to 2 years post-intervention
Average alcohol quantity
Average amount of alcohol consumed on drinking days
Measured: up to 2 years post-intervention
Secondary outcomes (4)
Amount of alcohol consumed
Total number of drinks consumed
Measured: up to 2 years post-intervention
Maximum daily alcohol
Highest number of drinks consumed on one day
Measured: up to 2 years post-intervention
Use of flush cures
Proportion of drinking days used flush cures
Measured: up to 2 years post-intervention
Use of drinking behavioral strategies
Proportion of drinking days used behavioral strategies
Measured: up to 2 years post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2026
- Study start18 Aug 2026 (estimated)
- Primary completion28 Feb 2029 (estimated)
- Study completion31 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Responsible party
- Principal investigator, Susan Luczak, University of Southern California
- Investigators
- Susan Luczak, PhD, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07657221
- Sponsor's protocol ID
- UP-24-00754
- Other IDs
- R01AA032036
- Status last verified
- Jun 2026
- First submitted
- 9 Jun 2026
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: For participants who agree to have their data included, de-identified participant data will be uploaded to the National Institute of Mental Health Data Archive (NDA).
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Alcohol Metabolism and Disease Risk in Asians: Examining the Impact of Personalized Phenotypic/Genotypic Feedback on Early Drinking Trajectories
- ClinicalTrials.gov ID
- NCT07657221
- Acronym / sponsor ID
- UP-24-00754
- Conditions
- Healthy, Alcohol Consumption
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Study start
- 18 Aug 2026 (estimated)
- Primary completion
- 28 Feb 2029 (estimated)
- Study completion
- 31 Aug 2030 (estimated)
- First posted
- 18 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. The main research question is: can we affect young adult behaviors through communication about these health-related risks? Participants will be asked to complete an in-person baseline session where they provide a DNA sample, complete online surveys, and do a brief interview. They will then receive one of several brief online information sessions and be followed in online surveys approximately every 3 months over the next 2 years.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| PHEN | Experimental | Behavioral: PHEN feedbackprovided phenotypic feedback |
| GENE | Experimental | Behavioral: PHEN feedback, Genetic: PHEN+GENE Feedbackprovides genotypic feedback |
| CONTROL | Placebo comparator | Other: Controlprovided a control feedback |
Who may qualify
- Ages
- 17 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- USC student of Chinese, Japanese, Korean, or Vietnamese heritage
Key exclusion criteria (1 listed)
- not a USC student, not 17-25 years old, not of Chinese, Japanese, Korean, or Vietnamese heritage
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PHEN feedbackFeedback on alcohol response (phenotype) | Behavioural | GENE, PHEN |
| PHEN+GENE FeedbackFeedback on both phenotype and genotype (PHEN+GENE) | Genetic | GENE |
| ControlFeedback that serves as control | Other | CONTROL |
Primary outcome
Drinking frequency
Time frame: up to 2 years post-intervention
Number of days consumed alcohol
Average alcohol quantity
Time frame: up to 2 years post-intervention
Average amount of alcohol consumed on drinking days
4 secondary outcomes
Amount of alcohol consumed
Time frame: up to 2 years post-intervention
Maximum daily alcohol
Time frame: up to 2 years post-intervention
Use of flush cures
Time frame: up to 2 years post-intervention
Use of drinking behavioral strategies
Time frame: up to 2 years post-intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Individual participant dataSharing planned: Yes. For participants who agree to have their data included, de-identified participant data will be uploaded to the National Institute of Mental Health Data Archive (NDA).
Related trials for Healthy
Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
Trained Athletes, Untrained
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
RecruitingPhase 1
A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Susan Luczak, PhD principal investigator
University of Southern California
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PHEN feedback and PHEN+GENE Feedback in people with Healthy and Alcohol Consumption, run by University of Southern California at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Susan Luczak, PhD (2137402203, luczak@usc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Drinking frequency (time frame: up to 2 years post-intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.